Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.

Erlanson DA, Arndt JW, Cancilla MT, Cao K, Elling RA, English N, Friedman J, Hansen SK, Hession C, Joseph I, Kumaravel G, Lee WC, Lind KE, McDowell RS, Miatkowski K, Nguyen C, Nguyen TB, Park S, Pathan N, Penny DM, Romanowski MJ, Scott D, Silvian L, Simmons RL, Tangonan BT, Yang W, Sun L.

Bioorg Med Chem Lett. 2011 May 15;21(10):3078-83. doi: 10.1016/j.bmcl.2011.03.032. Epub 2011 Mar 17.

PMID:
21459573
2.

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.

Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E, Jenkins TJ, Romanowski MJ, Baker DP, Silvian LF.

Protein Sci. 2010 Mar;19(3):429-39. doi: 10.1002/pro.321.

3.

Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration.

Watanabe K, Bianco C, Strizzi L, Hamada S, Mancino M, Bailly V, Mo W, Wen D, Miatkowski K, Gonzales M, Sanicola M, Seno M, Salomon DS.

J Biol Chem. 2007 Oct 26;282(43):31643-55. Epub 2007 Aug 24.

4.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.

Cancer Res. 2006 Oct 1;66(19):9617-24.

5.

An intermediate pH unfolding transition abrogates the ability of IgE to interact with its high affinity receptor FcepsilonRIalpha.

Demarest SJ, Hopp J, Chung J, Hathaway K, Mertsching E, Cao X, George J, Miatkowski K, LaBarre MJ, Shields M, Kehry MR.

J Biol Chem. 2006 Oct 13;281(41):30755-67. Epub 2006 Aug 11.

6.

Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters.

Arduini RM, Li Z, Rapoza A, Gronke R, Hess DM, Wen D, Miatkowski K, Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R, Chen LL, Chen L, Betzenhauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP.

Protein Expr Purif. 2004 Apr;34(2):229-42.

PMID:
15003256
7.

Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.

Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M.

J Clin Invest. 2003 Aug;112(4):575-87.

8.

Fucosylation of Cripto is required for its ability to facilitate nodal signaling.

Schiffer SG, Foley S, Kaffashan A, Hronowski X, Zichittella AE, Yeo CY, Miatkowski K, Adkins HB, Damon B, Whitman M, Salomon D, Sanicola M, Williams KP.

J Biol Chem. 2001 Oct 12;276(41):37769-78. Epub 2001 Aug 10.

9.

The murine anti-human common gamma chain monoclonal antibody CP.B8 blocks the second step in the formation of the intermediate affinity IL-2 receptor.

Baker DP, Whitty A, Zafari MR, Olson DL, Hession CA, Miatkowski K, Avedissian LS, Foley SF, McKay ML, Benjamin CD, Burkly LC.

Biochemistry. 1998 Oct 13;37(41):14337-49.

PMID:
9772159
10.

Identification of a palmitic acid-modified form of human Sonic hedgehog.

Pepinsky RB, Zeng C, Wen D, Rayhorn P, Baker DP, Williams KP, Bixler SA, Ambrose CM, Garber EA, Miatkowski K, Taylor FR, Wang EA, Galdes A.

J Biol Chem. 1998 May 29;273(22):14037-45.

11.

Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.

Mackay F, Bourdon PR, Griffiths DA, Lawton P, Zafari M, Sizing ID, Miatkowski K, Ngam-ek A, Benjamin CD, Hession C, Ambrose CM, Meier W, Browning JL.

J Immunol. 1997 Oct 1;159(7):3299-310.

PMID:
9317128
12.

Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.

Browning JL, Sizing ID, Lawton P, Bourdon PR, Rennert PD, Majeau GR, Ambrose CM, Hession C, Miatkowski K, Griffiths DA, Ngam-ek A, Meier W, Benjamin CD, Hochman PS.

J Immunol. 1997 Oct 1;159(7):3288-98.

PMID:
9317127
13.

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.

Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, Miatkowski K, Olson D, Parish TH, Rosa MD, Oleson FB, Hsu YM, Padlan EA, Letvin NL, Burkly LC.

AIDS Res Hum Retroviruses. 1997 Jul 20;13(11):933-43.

PMID:
9223409
14.

Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta.

Browning JL, Miatkowski K, Griffiths DA, Bourdon PR, Hession C, Ambrose CM, Meier W.

J Biol Chem. 1996 Apr 12;271(15):8618-26.

15.

Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines.

Browning JL, Miatkowski K, Sizing I, Griffiths D, Zafari M, Benjamin CD, Meier W, Mackay F.

J Exp Med. 1996 Mar 1;183(3):867-78.

16.

Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers.

Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS.

Ther Immunol. 1995 Jun;2(3):159-71.

PMID:
8885134
17.

Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.

Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, et al.

J Immunol. 1995 Jan 1;154(1):33-46.

PMID:
7995952

Supplemental Content

Loading ...
Support Center